Cannabis Products: FDA Asks Dosing, Research Incentive Questions
Executive Summary
The public hearing on cannabis and cannabis-derivative products also included calls for Good Manufacturing Practices to be imposed.
You may also be interested in...
‘Alternative Pathway’ Products Are Key New Challenge For FDA, Woodcock Says
US FDA will have to wrestle with a proliferation of medical products that are coming to market via ‘alternative pathways’ that do not neatly fit under – or sometimes deliberately seek to avoid – the agency’s regulatory authorities, acting commissioner says.
US FDA’s Human Drugs Program Suffers In Adjustment Of Agency Priorities
President Trump's budget request would boost compounding and vaccines by $5m, but human drugs program would lose $4.8m in training funds.
Deal Watch: Pfizer Licenses Skin-Targeted JAK Inhibitor Portfolio From Theravance
Deal with Pfizer makes for Theravance’s third large pharma partnership since 2016. AbbVie off-loads Marinol to India’s Alkem, Bausch licenses candidate for rare form of dry eye disease from Novaliq.